Kuur Therapeutics
https://kuurtx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kuur Therapeutics
Finance Watch: Kymera Will Start Protein Degrader Clinical Trials With $102m VC Round
Private Company Edition: Kymera said it will take up to three programs into the clinic by next year. Also, three new life science funds recently launched, including a Gates Foundation-backed accelerator for COVID-19 treatments, and Cell Medica reemerges as Kuur with new funding for CAR-NKT therapies.
Venture Funding Deals: CNS Plays Are Attracting Investment
Polyneuron, Synerkine, Harmony, EIP Pharma and AITI Life Sciences all raised cash in recent weeks to tackle various conditions involving the nervous system. More recent venture funding deals...
Interview: Altan Eyes Opportunities In US Pain Market
The Irish specialty pharma has made its first filing in the US with an infusion of acetaminophen that Altan hopes will break the monopoly of Mallinckrodt's Ofirmev.
CEO of New UK Cell And Gene Therapy Hub Says 'All Systems Are Go'
CEO of the Stevenage-based center hopes the new cell and gene manufacturing hub will see a growing life sciences ecosystem coalesce around it.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Catapult Therapy TCR Limited
- Cell Medica Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice